Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 19,297 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Friday, May 30th, Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60.

Alnylam Pharmaceuticals Trading Up 0.9%

Alnylam Pharmaceuticals stock traded up $2.69 during midday trading on Thursday, hitting $308.00. 761,150 shares of the stock were exchanged, compared to its average volume of 929,502. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $40.16 billion, a price-to-earnings ratio of -141.93 and a beta of 0.17. The stock's 50-day simple moving average is $262.51 and its 200 day simple moving average is $256.16. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $147.25 and a fifty-two week high of $310.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Strs Ohio purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $7,781,000. Geneos Wealth Management Inc. raised its stake in Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 175 shares during the last quarter. IFM Investors Pty Ltd lifted its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the first quarter. IFM Investors Pty Ltd now owns 23,850 shares of the biopharmaceutical company's stock worth $6,440,000 after purchasing an additional 150 shares during the period. Bayforest Capital Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 39 shares in the last quarter. Finally, SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $46,194,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ALNY shares. UBS Group lifted their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Finally, Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.